alexa VEGF-A and VEGF-R1/2 Expression: Critical Importance in
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

VEGF-A and VEGF-R1/2 Expression: Critical Importance in Different Stages of Human Gastric Adenocarcinoma

Christian Prinz*

Helios Klinikum Wuppertal, Medizinische Klinik, University of Witten, Germany

Corresponding Author:
Christian Prinz
Medizinische Klinik 2
Helios Klinikum Wuppertal
University of Witten/Herdecke
Germany, 42283 Wuppertal, Germany
Tel: 0049-202-896-2243
E-mail: [email protected]

Received Date: November 18, 2013; Accepted Date: December 27, 2013; Published Date: January 07, 2014

Citation: Prinz C (2014) VEGF-A and VEGF-R1/2 Expression: Critical Importance in Different Stages of Human Gastric Adenocarcinoma. J Gastroint Dig Syst 3:160. doi: 10.4172/2161-069X.1000160

Copyright: © 2014 Prinz C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



A key role for gastric micro vascularisation during cancer progression is the vascular growth factor VEGF-A. In gastric cancer, serum VEGF levels were also significantly higher in patients with advanced-stage cancer, higher lymph node ratio, and peritoneal invasion. Inhibition of VEGF or blockade of the corresponding VEGF-R1 and VEGF-R2 receptors has been investigated in the treatment of gastric adenocarcinoma. Treatment of VEGF-antibodies or VEGF-receptor antibodies, however, had no significant effect on overall survival. Most recently, however, a new and fully humanized IgG1 monoclonal antibody Ramucirumab (IMC-1121B) has been introduced, which targets the extracellular domain of VEGF receptor 2 (VEGFR2). The antibody, increasing the median overall survival compared to placebo. Thus, a more detailed analysis of VEGF and VEGF receptor expression in early compared to advanced stages is needed. The current review focuses on previous findings and describes own results in early compared to advanced stages of gastric adenocarcinoma. A special focus is given on VEGF-A expression as well as the expression of the corresponding receptors VEGF-R1 and VEGF-R2. Own data reveal that VEGF-R2 may be a better target since expression levels seem to be expressed at high levels in gastric cancer tissues


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version